Crucell Announces Start of Universal RSV Vaccine Program
Crucell N.V. (Leiden, the Netherlands) has begun a discovery program for the development and commercialization of a universal respiratory syncytial virus (RSV) vaccine.
Crucell N.V. (Leiden, the Netherlands) has begun a discovery program for the development and commercialization of a universal respiratory syncytial virus (RSV) vaccine. The RSV vaccine will be designed to prevent severe infections with the most common RSV strains in infants and the elderly. This RSV program is part of an existing strategic collaboration with Johnson & Johnson, through its subsidiary Ortho-McNeil-Janssen Pharmaceuticals, Inc., that was signed in September 2009.
The September 2009 for the development of a universal monoclonal antibody product for the treatment and prevention of influenza A. It also involves four programs that focus on the development of a universal influenza A vaccine and products directed against three other disease targets. Activities for the universal influenza A vaccine started in January. The design of the universal influenza A vaccine will be based on specific epitopes (binding sites) that are recognized by broadly cross-neutralizing influenza antibodies. The universal RSV vaccine has been selected as the second innovation program; selection of the two other innovation targets is ongoing.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
